CYP19A1 and breast cancer: Hormone receptor-positive breast cancer (HR+ BC) accounts for the majority of breast cancer cases and is primarily treated using endocrine therapies, including selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), and selective estrogen receptor degraders (SERDs).